2022
DOI: 10.1007/s12028-022-01459-6
|View full text |Cite
|
Sign up to set email alerts
|

Pregabalin for Recurrent Seizures in Critical Illness: A Promising Adjunctive Therapy, Especially for cyclic Seizures

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 28 publications
0
2
0
Order By: Relevance
“…A second study by Dhakal et al 15 of gabapentin in post‐SAH patients noted that opioid use was decreasing as gabapentin dosing was increased in these patients, but the primary outcome of the study was safety and tolerability in which only minimal adverse effects were noted in these patients. Additionally, the actions of gabapentinoids confer the additional benefits of their anxiolytic, antiemetic, and antiseizure properties 9,67,68 . The antiseizure effects of gabapentinoids may be of particular interest as epilepsy is a known complication of SAH, with an incidence ranging from 0.9% to 25%, and despite a paucity of studies focusing on SAH, Alvarez‐Sabín et al 69 demonstrated 80% seizure remission in post‐stroke epilepsy with gabapentin monotherapy.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…A second study by Dhakal et al 15 of gabapentin in post‐SAH patients noted that opioid use was decreasing as gabapentin dosing was increased in these patients, but the primary outcome of the study was safety and tolerability in which only minimal adverse effects were noted in these patients. Additionally, the actions of gabapentinoids confer the additional benefits of their anxiolytic, antiemetic, and antiseizure properties 9,67,68 . The antiseizure effects of gabapentinoids may be of particular interest as epilepsy is a known complication of SAH, with an incidence ranging from 0.9% to 25%, and despite a paucity of studies focusing on SAH, Alvarez‐Sabín et al 69 demonstrated 80% seizure remission in post‐stroke epilepsy with gabapentin monotherapy.…”
Section: Methodsmentioning
confidence: 99%
“…Additionally, the actions of gabapentinoids confer the additional benefits of their anxiolytic, antiemetic, and antiseizure properties. 9,67,68 The antiseizure effects of gabapentinoids may be of particular interest as epilepsy is a known complication of SAH, with an incidence ranging from 0.9% to 25%, and despite a paucity of studies focusing on SAH, Alvarez-Sabín et al 69 demonstrated 80% seizure remission in post-stroke epilepsy with gabapentin monotherapy. Although not extensively studied in post-SAH headache, there is some promising evidence that these medications could be effective analgesics while also decreasing seizure risk and potentially having a more benign side-effect profile than opioids or medications that could increase risk of re-bleed, such as non-steroidal anti-inflammatory drugs (NSAIDs).…”
Section: Gabapentinoids and Cortical Spreading Depressionmentioning
confidence: 99%